If you've ever used the popular DNA testing service 23andMe, you might be in line for a major payday from a class-action lawsuit. Last fall, the company revealed that it suffered a data breach ...

Affected by the 23andMe Hack? How to Submit a Claim and (Maybe) Get $10K As part of its bankruptcy proceeding, 23andMe is asking those impacted by the 2023 'DNA Relatives' hack to submit a claim by ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.

A nonprofit controlled by Anne Wojcicki, former chief executive of 23andMe, has won the bidding process to buy the bankrupt genetic testing company. If approved by the court, the sale would put ...

Drugmaker Regeneron Pharmaceuticals is acquiring majority assets of bankrupt genetic testing firm 23andMe Holding for $256 million. The once-sizzling DNA-testing startup filed for bankruptcy in March, ...

SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court greenlight. That means Wojcicki’s nonprofit TTAM Research Institute will ...

PCMag editors select and review products independently. If you buy through affiliate links, we may earn commissions, which help support our testing. Another day, another opportunity to claim a ...

(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy ...